Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells

There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especially post-myeloproliferative neoplasm (MPN) secondary (s) AML. Studies presented describe effects of genetic knockout, degradation or small molecule targeted-inhibition of GFI1/LSD1 on active enhancers...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Cancer J
Asıl Yazarlar: Fiskus, Warren, Mill, Christopher P., Nabet, Behnam, Perera, Dimuthu, Birdwell, Christine, Manshouri, Taghi, Lara, Bernardo, Kadia, Tapan M., DiNardo, Courtney, Takahashi, Koichi, Daver, Naval, Bose, Prithviraj, Masarova, Lucia, Pemmaraju, Naveen, Kornblau, Steven, Borthakur, Gautam, Montalban-Bravo, Guillermo, Manero, Guillermo Garcia, Sharma, Sunil, Stubbs, Matthew, Su, Xiaoping, Green, Michael R., Coarfa, Cristian, Verstovsek, Srdan, Khoury, Joseph D., Vakoc, Christopher R., Bhalla, Kapil N.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8138012/
https://ncbi.nlm.nih.gov/pubmed/34016956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00487-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller